American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

@article{Reddy2015AmericanGA,
  title={American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.},
  author={K. Rajender Reddy and Kimberly L Beavers and Sarah P. Hammond and Joseph K. Lim and Yngve Falck-Ytter},
  journal={Gastroenterology},
  year={2015},
  volume={148 1},
  pages={
          215-9; quiz e16-7
        }
}
Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, South Carolina; Division of Infectious Diseases, Brigham & Women’s Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts; Division of Gastroenterology and Hepatology, Yale University School of Medicine, New Haven, Connecticut; and Division of Gastroenterology and… 
View on PubMed
gastrojournal.org
460 Citations
Highly Influential Citations
28
Background Citations
123
Methods Citations
10
Results Citations
5

Tables from this paper

460 Citations

American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston,…

Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases

Members of IBD research group of the Korean Association for the Study of Intestinal Diseases have produced a guideline on the prevention and management of viral hepatitis in IBD.

The Importance of Antiviral Prophylaxis against Hepatitis B Virus in Patients under Immunosuppressive Therapy

Ad dress for Cor res pon den ce: Firdevs Aksoy MD, Karadeniz Technical University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Trabzon, Turkey E-mail:…

Hepatology Clearance for Immunomodulation in Patients With Hepatitis B

  • Tae Hoon LeeT. Schiano
  • Medicine, Biology
    Clinical liver disease
  • 2019
Reactivation of HBV with the use of immune modulation therapy may lead to decompensation of chronic liver disease, resulting in significant morbidity and mortality, and the risk for HBV reactivation needs to be assessed carefully in all patients prior to the initiation ofimmune modulation therapy.

Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases

This practice guideline/guidance constitutes an update of the guidelines on AIH published in 2010 by the American Association for the Study of Liver Diseases (AASLD) and updates the epidemiology, diagnosis, management, and outcomes of AIH in adults and children.

Acute viral Hepatitis B infection after hematopoietic stem cell transplantation in a vaccine-immune patient

Pınar Korkmaz1, Hasan Naz2, Özgür Mehtap3, Demet Çekdemir4, Duru Mıstanoğlu Özatağ1 1 Department of Infectious Diseases and Clinical Microbiology, Kütahya Health Sciences University, Faculty of…

Diagnosis, Management, and Prevention of Hepatitis B Reactivation

The challenges surrounding the management of HBV reactivation include a lack of awareness of this phenomenon, heterogeneity in clinical practice for CHB, and a paucity of data to guide clinicians in the prevention and treatment of reactivation.

Awareness of Hepatitis B Virus Reactivation Among Physicians Administering Immunosuppressive Treatment and Related Clinical Practices

According to the results obtained in the study, the rates of conducting screening and awareness of HBV reactivation among physicians administering immunosuppressive treatment were higher compared with similar studies; however, their awareness that HBV DNA and anti-HBc should be utilized much more frequently among the serological tests they use for screening ofHBV infection, should be increased.

Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement

An Australian consensus statement is developed with infectious diseases, hepatology, haematology and oncology specialists to inform hepatitis B screening and antiviral management for immunocompromised patients with haem atological and solid organ malignancies in Australia.

Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

The goals of the 2018 HBV management guidelines are to highlight the public health impact of HBV infection in Canada and the need to improve diagnosis and linkage to care, and recommend current best-practice guidelines for treatment ofHBV.
...

References

SHOWING 1-3 OF 3 REFERENCES

American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston,…

The AGA institute process for developing clinical practice guidelines part one: grading the evidence.

  • S. SultanY. Falck-YtterJ. Inadomi
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2013

AGA Institute clinical practice guideline development process

  • 2013